These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1283 related items for PubMed ID: 28341329

  • 21. Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays.
    Sarkar S, Jacob KS, Pratheesh R, Chacko AG.
    Acta Neurochir (Wien); 2014 Jul; 156(7):1379-87; discussion 1387. PubMed ID: 24781680
    [Abstract] [Full Text] [Related]

  • 22. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
    Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernández I, Molina M, Mercado M.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
    [Abstract] [Full Text] [Related]

  • 23. "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.
    Butz LB, Sullivan SE, Chandler WF, Barkan AL.
    Pituitary; 2016 Dec; 19(6):547-551. PubMed ID: 27497970
    [Abstract] [Full Text] [Related]

  • 24. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
    Tamanini JVG, Dal Fabbro M, de Freitas LLL, Vassallo J, de Souza Queiroz L, Rogerio F.
    Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
    [Abstract] [Full Text] [Related]

  • 25. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and complications of neurosurgical treatment of acromegaly.
    Krzentowska-Korek A, Gołkowski F, Bałdys-Waligórska A, Hubalewska-Dydejczyk A.
    Pituitary; 2011 Jun; 14(2):157-62. PubMed ID: 21107739
    [Abstract] [Full Text] [Related]

  • 27. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC, Rossi A, Martinelli CE, Machado HR, Moreira AC.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Serum phosphate: Does it more closely reflect the true state of acromegaly?
    Xie T, Tian P, Wu S, Zhang X, Liu T, Gu Y, Sun C, Hu F.
    J Clin Neurosci; 2020 Jan; 71():26-31. PubMed ID: 31859176
    [Abstract] [Full Text] [Related]

  • 30. Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly.
    Valdemarsson S, Ljunggren S, Bramnert M, Norrhamn O, Nordström CH.
    J Intern Med; 2000 Jun; 247(6):640-50. PubMed ID: 10886485
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M, Akin F, Yaylali GF.
    Neuroendocrinology; 2007 Jun; 86(2):119-23. PubMed ID: 17671378
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Quantification of specific growth patterns and frequency of the empty sella phenomenon in growth hormone-secreting pituitary adenomas.
    Bier G, Hempel JM, Grimm F, Ernemann U, Bender B, Honegger J.
    Eur J Radiol; 2018 Jul; 104():79-86. PubMed ID: 29857870
    [Abstract] [Full Text] [Related]

  • 35. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly.
    Jung IH, Choi S, Ku CR, Lee SG, Lee EJ, Kim SH, Kim EH.
    J Clin Endocrinol Metab; 2021 Jun 16; 106(7):e2589-e2599. PubMed ID: 33738470
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS.
    Clin Endocrinol (Oxf); 2011 Aug 16; 75(2):220-5. PubMed ID: 21521288
    [Abstract] [Full Text] [Related]

  • 38. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.
    Horm Metab Res; 2010 Jan 16; 42(1):50-5. PubMed ID: 19798623
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.